iPAX‑2 Trial of TLX101 TX in First‑Line Glioblastoma Finishes Enrollment and Locks In Dosing Schedule
Plus Therapeutics Soars as UnitedHealthcare Paves Way for Groundbreaking Brain Cancer Treatment
Breakthrough Hope: AbbVie's Next-Gen Alopecia Drug Shows Staggering Results in Late-Stage Trial